Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.99
PFE's Cash to Debt is ranked higher than
68% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. PFE: 0.99 )
PFE' s 10-Year Cash to Debt Range
Min: 0.14   Max: 3.47
Current: 0.99

0.14
3.47
Equity to Asset 0.42
PFE's Equity to Asset is ranked higher than
56% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. PFE: 0.42 )
PFE' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.62
Current: 0.42

0.42
0.62
F-Score: 6
Z-Score: 2.70
M-Score: -2.76
WACC vs ROIC
7.53%
11.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.62
PFE's Operating margin (%) is ranked higher than
94% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. PFE: 25.62 )
PFE' s 10-Year Operating margin (%) Range
Min: 9.51   Max: 35.89
Current: 25.62

9.51
35.89
Net-margin (%) 18.42
PFE's Net-margin (%) is ranked higher than
92% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.01 vs. PFE: 18.42 )
PFE' s 10-Year Net-margin (%) Range
Min: 8.74   Max: 42.65
Current: 18.42

8.74
42.65
ROE (%) 12.02
PFE's ROE (%) is ranked higher than
85% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. PFE: 12.02 )
PFE' s 10-Year ROE (%) Range
Min: 9.16   Max: 55.34
Current: 12.02

9.16
55.34
ROA (%) 5.33
PFE's ROA (%) is ranked higher than
79% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. PFE: 5.33 )
PFE' s 10-Year ROA (%) Range
Min: 4.05   Max: 27.83
Current: 5.33

4.05
27.83
ROC (Joel Greenblatt) (%) 65.10
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.87 vs. PFE: 65.10 )
PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 24.42   Max: 95.19
Current: 65.1

24.42
95.19
Revenue Growth (3Y)(%) -2.30
PFE's Revenue Growth (3Y)(%) is ranked higher than
61% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. PFE: -2.30 )
PFE' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.5   Max: 19.1
Current: -2.3

-2.5
19.1
EBITDA Growth (3Y)(%) -1.60
PFE's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. PFE: -1.60 )
PFE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.7   Max: 35.5
Current: -1.6

-4.7
35.5
EPS Growth (3Y)(%) 10.00
PFE's EPS Growth (3Y)(%) is ranked higher than
79% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. PFE: 10.00 )
PFE' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.8   Max: 90.5
Current: 10

-26.8
90.5
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PFE Guru Trades in Q1 2014

Louis Moore Bacon 200,452 sh (New)
John Hussman 17,000 sh (New)
Caxton Associates 100,000 sh (New)
Paul Tudor Jones 875,000 sh (+1792.01%)
Joel Greenblatt 1,014,808 sh (+356.54%)
Steven Cohen 295,765 sh (+185.50%)
David Dreman 11,851 sh (+16.61%)
Irving Kahn 2,112,819 sh (+11.22%)
Diamond Hill Capital 8,790,937 sh (+5.42%)
John Buckingham 65,971 sh (+4.66%)
Murray Stahl 62,855 sh (+2.03%)
Ray Dalio 112,108 sh (+1.54%)
RS Investment Management 2,080,155 sh (+0.38%)
Louis Moore Bacon 600,000 sh (unchged)
Michael Price 347,100 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 11,022 sh (unchged)
Bill Frels 2,561,304 sh (-0.34%)
HOTCHKIS & WILEY 194,200 sh (-0.36%)
Charles Brandes 5,743,711 sh (-0.41%)
Ken Fisher 30,242,537 sh (-1.25%)
Mario Gabelli 1,165,574 sh (-1.53%)
Dodge & Cox 64,121,017 sh (-1.79%)
James Barrow 59,895,571 sh (-2.55%)
Pioneer Investments 8,653,390 sh (-4.15%)
John Keeley 95,893 sh (-8.21%)
Jeff Auxier 145,881 sh (-8.44%)
Ronald Muhlenkamp 41,169 sh (-8.77%)
Manning & Napier Advisors, Inc 899,181 sh (-12.47%)
NWQ Managers 9,231,207 sh (-13.60%)
Jean-Marie Eveillard 7,866,473 sh (-22.77%)
Vanguard Health Care Fund 7,276,622 sh (-40.13%)
Jeremy Grantham 6,741,800 sh (-74.85%)
Jim Simons 454,241 sh (-93.94%)
» More
Q2 2014

PFE Guru Trades in Q2 2014

Jim Simons 9,649,941 sh (+2024.41%)
Ray Dalio 393,008 sh (+250.56%)
Vanguard Health Care Fund 14,934,022 sh (+105.23%)
Joel Greenblatt 1,741,314 sh (+71.59%)
David Dreman 13,615 sh (+14.88%)
RS Investment Management 2,344,681 sh (+12.72%)
Louis Moore Bacon 225,118 sh (+12.31%)
Diamond Hill Capital 9,378,812 sh (+6.69%)
Charles Brandes 6,075,460 sh (+5.78%)
Ken Fisher 31,482,489 sh (+4.10%)
James Barrow 60,500,058 sh (+1.01%)
John Buckingham 66,601 sh (+0.95%)
Irving Kahn 2,124,489 sh (+0.55%)
Bill Frels 2,573,296 sh (+0.47%)
Murray Stahl 62,961 sh (+0.17%)
Brian Rogers 12,287,115 sh (unchged)
Louis Moore Bacon 1,100,000 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Eric Mindich 3,464,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Jana Partners 250,000 sh (unchged)
John Hussman Sold Out
Caxton Associates Sold Out
Jeff Auxier 145,656 sh (-0.15%)
Ruane Cunniff 10,987 sh (-0.32%)
Ronald Muhlenkamp 41,019 sh (-0.36%)
Manning & Napier Advisors, Inc 882,317 sh (-1.88%)
Mario Gabelli 1,104,070 sh (-5.28%)
John Keeley 89,839 sh (-6.31%)
Pioneer Investments 7,003,706 sh (-19.06%)
Dodge & Cox 48,902,097 sh (-23.73%)
NWQ Managers 6,363,006 sh (-31.07%)
HOTCHKIS & WILEY 128,800 sh (-33.68%)
Michael Price 107,100 sh (-69.14%)
Jean-Marie Eveillard 2,303,762 sh (-70.71%)
Jeremy Grantham 349,508 sh (-94.82%)
Paul Tudor Jones 16,200 sh (-98.15%)
» More
Q3 2014

PFE Guru Trades in Q3 2014

Steven Cohen 450,000 sh (New)
Paul Tudor Jones 105,737 sh (+552.70%)
Jeremy Grantham 1,111,454 sh (+218.01%)
David Dreman 15,040 sh (+10.47%)
Diamond Hill Capital 10,195,767 sh (+8.71%)
John Keeley 97,339 sh (+8.35%)
RS Investment Management 2,437,555 sh (+3.96%)
Brian Rogers 12,737,115 sh (+3.66%)
Charles Brandes 6,257,090 sh (+2.99%)
James Barrow 62,170,881 sh (+2.76%)
Bill Frels 2,630,017 sh (+2.20%)
John Buckingham 67,724 sh (+1.69%)
Ken Fisher 31,702,495 sh (+0.70%)
Murray Stahl 63,028 sh (+0.11%)
Louis Moore Bacon 600,000 sh (unchged)
Pioneer Investments 3,512,725 sh (unchged)
Vanguard Health Care Fund 14,934,022 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Eric Mindich 1,500,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY Sold Out
Jeff Auxier 145,628 sh (-0.02%)
Ruane Cunniff 10,967 sh (-0.18%)
NWQ Managers 6,338,458 sh (-0.39%)
Dodge & Cox 47,604,980 sh (-2.65%)
Ronald Muhlenkamp 39,499 sh (-3.71%)
Manning & Napier Advisors, Inc 842,466 sh (-4.52%)
Irving Kahn 1,985,161 sh (-6.56%)
Joel Greenblatt 1,622,092 sh (-6.85%)
Mario Gabelli 1,023,581 sh (-7.29%)
Ray Dalio 295,108 sh (-24.91%)
Michael Price 47,100 sh (-56.02%)
Louis Moore Bacon 50,000 sh (-77.79%)
Jean-Marie Eveillard 135,661 sh (-94.11%)
» More
Q4 2014

PFE Guru Trades in Q4 2014

Bestinfond 635,978 sh (New)
Richard Pzena 2,170,568 sh (New)
Jean-Marie Eveillard 5,272,943 sh (+3786.85%)
Louis Moore Bacon 550,000 sh (+1000.00%)
Paul Tudor Jones 385,500 sh (+264.58%)
Steven Cohen 1,211,300 sh (+169.18%)
Pioneer Investments 5,414,346 sh (+54.14%)
Vanguard Health Care Fund 19,395,622 sh (+29.88%)
RS Investment Management 2,719,255 sh (+11.56%)
Manning & Napier Advisors, Inc 883,569 sh (+4.88%)
Diamond Hill Capital 10,612,885 sh (+4.09%)
John Keeley 99,959 sh (+2.69%)
Murray Stahl 64,055 sh (+1.63%)
Bill Frels 2,657,601 sh (+1.05%)
James Barrow 62,760,163 sh (+0.95%)
Robert Bruce 455,332 sh (+0.74%)
Charles Brandes 6,272,097 sh (+0.24%)
NWQ Managers 6,349,377 sh (+0.17%)
Prem Watsa 235,000 sh (unchged)
Brian Rogers 12,737,115 sh (unchged)
Ruane Cunniff 10,967 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Eric Mindich 1,500,000 sh (unchged)
Michael Price Sold Out
John Buckingham 67,663 sh (-0.09%)
Jeff Auxier 144,678 sh (-0.65%)
Dodge & Cox 47,195,573 sh (-0.86%)
Ken Fisher 31,196,415 sh (-1.60%)
David Dreman 14,792 sh (-1.65%)
Ronald Muhlenkamp 38,409 sh (-2.76%)
Irving Kahn 1,883,217 sh (-5.14%)
Mario Gabelli 951,583 sh (-7.03%)
Joel Greenblatt 1,420,948 sh (-12.40%)
Ray Dalio 211,208 sh (-28.43%)
Jeremy Grantham 33,931 sh (-96.95%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc - Jul 25, 2014

Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

Richard Pzena's New Buys
Wharton School cum laude and Founder and Co-Chief Investment Officer of Pzena Investment Management LLC Richard Pzena (Trades, Portfolio) believes in investing in good businesses – but only when they go on sale. Read more...
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
Legendary Investor Irving Kahn's Top Five Stocks
One of America’s oldest and most respected value investors, Irving Kahn (Trades, Portfolio), and his fund Kahn Brothers recently reported their fourth quarter holdings which boasted several hefty reductions and one sell out. Over the past quarter Kahn added one new stock, and the guru now maintains 43 stocks valued at $687 million.
Read more...
Diamond Hill Capital Comments on Pfizer Inc
Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed. Read more...
Guru Favorites Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to:Have a dividend of greater than 3%. Have a strong history of stable and increasing dividends. Maintain Guru ownership. Have a market cap of greater than $10 billion.The following four companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.A comparison of the companies’ historical dividend growth:AT&T (T)On June 27, AT&T declared a dividend of $0.46 per share, representing 5.20% dividend yield for the company. This dividend is payable on August 1 to shareholders of the record at the close of business on July 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 4.40%- 5-year: 2.30%- 3-year: 2.30%AT&T is a communications holding company. Its subsidiaries and affiliates are the providers of AT&T services in the U.S. and internationally. The company holds a portfolio of the nation’s fastest and most reliable 4G LTE network, wireless internet, Wi-Fi and voice and cloud-based services.AT&T’s historical revenue and net income:The analysis on AT&T reports that the company’s price is near a 5-year high, it has issued $12.6 billion in debt over the past three years and its operating income has been in loss over the past three years. On the other hand the analysis also notes that the Piotroski F-Score is high, its dividend yield is near a 2-year high and its P/E, P/S and P/B ratios are all trading at around historical lows.The Peter Lynch Chart suggests that the company is currently undervalued:AT&T has a market cap of $184.3 billion. Its shares are currently trading at around $35.51 with a P/E ratio of 10.40 and a P/S ratio of 1.50. The company had an annual average earnings growth of 4.10% over the past ten years.Lockheed Martin (LMT)On June 26, Lockheed Martin declared a dividend of $1.33 per share, representing 3.20% dividend yield for the company. This dividend is payable on Sept. 26 to shareholders of the record at the close of business on Sept. 2, 2014.

The company’s historical dividend growth is as follows:- 10-year: 20.90%- 5-year: 20.70%- 3-year: 21.90%Lockheed Martin is a security company that is principally engaged in the research, design, development, manufacture, integration, and sustainment of advanced technology systems and products. It also provides a range of management, engineering, technical, scientific, logistic, and information services.Lockheed Martin’s historical revenue and earnings growth:The analysis on Lockheed Martin reports that the company’s revenue has been in decline over the past month, its dividend yield is near a 3-year low and its price is near a 10-year high.The Peter Lynch Chart suggests that the company is currently overvalued:Lockheed Martin has a market cap of $51.02 billion. Its shares are currently trading at around $160.75 with a P/E ratio of 16.50, a P/S ratio of 1.20 and a P/B ratio of 10.50. The company had an annual average earnings growth of 9.90% over the past ten years.GuruFocus rated Lockheed Martin the business predictability rank of 3-star.Pfizer (PFE)On June 26, Pfizer declared a dividend of $0.260 per share, representing 3.40% dividend yield for the company. This dividend is payable on Sept. 3 to shareholders of the record at the close of business on Aug. 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 1.20%- 5-year: 5.80%- 3-year: 10.10%Pfizer is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include areas of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.Pfizer’s historical revenue and net income:The analysis on Pfizer reports that the company’s revenue has been in decline over the past year, the dividend yield is near a 5-year low, the price is near a 5-year high and its operating margin is expanding.The Peter Lynch Chart suggests that the company is currently undervalued:Pfizer has a market cap of $192.19 billion. Its shares are currently trading at around $30.13 with a P/E ratio of 9.60, a P/S ratio of 4.00 and a P/B ratio of 2.70. The company had an annual average earnings growth of 3.40% over the past ten years.GuruFocus rated Pfizer the business predictability rank of 3-star.Freeport-McMoRan Copper & Gold (FCX)On June 25, Freeport-McMoRan declared a dividend of $0.313 per share, representing 3.40% dividend yield for the company. This dividend is payable on Aug. 1 to shareholders of the record at the close of business on July 15, 2014.

The company’s historical dividend growth is as follows:- 10-year: 0.00%- 5-year: 0.00%- 3-year: 40.60%Freeport-McMoRan is a U.S.-based natural resource company with an industry leading global portfolio of mineral assets, significant oil and gas resources and a growing production profile.Freeport-McMoRan’s historical revenue and net income:The analysis on Freeport-McMoRan reports that the company’s asset growth is faster than its revenue growth and its P/S ratio is close to a 2-year low.The Peter Lynch Chart shows that the company is currently undervalued:Freeport-McMoRan Copper & Gold has a market cap of $38.43 billion. Its shares are currently trading at around $37.00 with a P/E ratio of 15.10, a P/S ratio of 1.80 and a P/B ratio of 1.50. The dividend yield for the company is currently sitting at 3.40%.To view a complete list of high yielding dividend stocks found among the gurus’ portfolios, click here.

Try a free 7-day premium membership. Read more...
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014?
Pfizer (PFE) will release its first quarter 2014 earnings report before the opening bell on Monday, May 5, 2014. Since the company has posted higher than expected earnings over the past three quarters, analysts and investors are looking for the pharmaceutical giant to beat the Street’s estimates once again. Read more...
Pfizer and Lockheed Martin Top Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.50
PFE's P/E(ttm) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 52.50 vs. PFE: 24.50 )
PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 34.03
Current: 24.5

7.67
34.03
Forward P/E 15.06
PFE's Forward P/E is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.73 vs. PFE: 15.06 )
N/A
PE(NRI) 24.30
PFE's PE(NRI) is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.50 vs. PFE: 24.30 )
PFE' s 10-Year PE(NRI) Range
Min: 9.77   Max: 33.96
Current: 24.3

9.77
33.96
P/B 3.10
PFE's P/B is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. PFE: 3.10 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.09
Current: 3.1

1.32
4.09
P/S 4.50
PFE's P/S is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.38 vs. PFE: 4.50 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 5.38
Current: 4.5

1.72
5.38
PFCF 14.50
PFE's PFCF is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1165.60 vs. PFE: 14.50 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 27.64
Current: 14.5

5.02
27.64
POCF 13.13
PFE's POCF is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.96 vs. PFE: 13.13 )
PFE' s 10-Year POCF Range
Min: 4.56   Max: 22.01
Current: 13.13

4.56
22.01
EV-to-EBIT 16.72
PFE's EV-to-EBIT is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.80 vs. PFE: 16.72 )
PFE' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 24.8
Current: 16.72

7.9
24.8
PEG 5.52
PFE's PEG is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. PFE: 5.52 )
PFE' s 10-Year PEG Range
Min: 1.14   Max: 584
Current: 5.52

1.14
584
Shiller P/E 20.20
PFE's Shiller P/E is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.82 vs. PFE: 20.20 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 33.64
Current: 20.2

8.49
33.64
Current Ratio 2.67
PFE's Current Ratio is ranked higher than
74% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. PFE: 2.67 )
PFE' s 10-Year Current Ratio Range
Min: 1.15   Max: 2.67
Current: 2.67

1.15
2.67
Quick Ratio 2.41
PFE's Quick Ratio is ranked higher than
78% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. PFE: 2.41 )
PFE' s 10-Year Quick Ratio Range
Min: 0.87   Max: 2.41
Current: 2.41

0.87
2.41
Days Inventory 232.48
PFE's Days Inventory is ranked higher than
60% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.83 vs. PFE: 232.48 )
PFE' s 10-Year Days Inventory Range
Min: 142.41   Max: 412.93
Current: 232.48

142.41
412.93
Days Sales Outstanding 63.79
PFE's Days Sales Outstanding is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. PFE: 63.79 )
PFE' s 10-Year Days Sales Outstanding Range
Min: 45.78   Max: 106.89
Current: 63.79

45.78
106.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
PFE's Dividend Yield is ranked higher than
88% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. PFE: 3.00 )
PFE' s 10-Year Dividend Yield Range
Min: 1.65   Max: 10.4
Current: 3

1.65
10.4
Dividend Payout 0.74
PFE's Dividend Payout is ranked higher than
97% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.92 vs. PFE: 0.74 )
PFE' s 10-Year Dividend Payout Range
Min: 0.3   Max: 1.11
Current: 0.74

0.3
1.11
Dividend growth (3y) 9.10
PFE's Dividend growth (3y) is ranked higher than
81% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. PFE: 9.10 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 9.1

-14.7
22.6
Yield on cost (5-Year) 4.15
PFE's Yield on cost (5-Year) is ranked higher than
90% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 4.15 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.28   Max: 14.38
Current: 4.15

2.28
14.38
Share Buyback Rate 6.50
PFE's Share Buyback Rate is ranked higher than
98% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. PFE: 6.50 )
PFE' s 10-Year Share Buyback Rate Range
Min: 6.5   Max: -19
Current: 6.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
PFE's Price/DCF (Projected) is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.70 vs. PFE: 1.10 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 6.59
Current: 1.1

0.69
6.59
Price/Median PS Value 1.30
PFE's Price/Median PS Value is ranked higher than
77% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. PFE: 1.30 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 3.48
Current: 1.3

0.62
3.48
Price/Peter Lynch Fair Value 3.80
PFE's Price/Peter Lynch Fair Value is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. PFE: 3.80 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.21   Max: 15.03
Current: 3.8

1.21
15.03
Earnings Yield (Greenblatt) 6.00
PFE's Earnings Yield (Greenblatt) is ranked higher than
88% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. PFE: 6.00 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4   Max: 12.6
Current: 6

4
12.6
Forward Rate of Return (Yacktman) 12.59
PFE's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.09 vs. PFE: 12.59 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.7   Max: 21
Current: 12.59

8.7
21

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany, PFIZ34.Brazil, PFE.Mexico, PFE.Argentina, PFE.Chile,
Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its global resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. They managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products primarily prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, and genitourinary, major depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes worldwide revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its global biopharmaceutical businesses, they promote its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its major products. The Company is subject to extensive regulation by national, state and local agencies in the countries in which they do business.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
Biogen And Idec To Part Ways After Inventing Alzheimer's Drug Mar 27 2015 
DE Mar 24 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
A look at Jean-Marie Eveillard's investment in Pfizer Mar 17 2015 
Top Pharma Stock Picks For March Mar 13 2015 
Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
Pfizer Will Supply Drugs To UNICEF Mar 05 2015 


More From Other Websites
What Products Affect Pfizer’s Revenue? Mar 30 2015
Biopharmaceutical Business: Why It’s Important for Pfizer Mar 30 2015
Busiest Day for Health-Care Deals Is Set to Spawn More: Real M&A Mar 30 2015
Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology... Mar 30 2015
Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology... Mar 30 2015
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog Mar 30 2015
Analyzing Pfizer’s Business Segments Mar 30 2015
Pain and Erectile Dysfunction Make Pfizer Biggest in Drug Ads Mar 30 2015
The Best Performing Stocks of 2015 in the S&P 500 Mar 29 2015
GSK agrees UK deal for meningitis shot after Novartis stand-off Mar 29 2015
Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015
The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
Four horsemen of semis & biotech: Cramer Mar 27 2015
Pfizer: A Leading Pharmaceutical Company Mar 27 2015
11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
Stocks higher; Nasdaq leads as biotechs recover Mar 27 2015
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference Mar 26 2015
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference Mar 26 2015
Merger momentum keeps on rolling with Heinz deal for Kraft Mar 25 2015
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD):... Mar 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK